Mergers and Acquisitions — Both Successful and Failed — Dominated the NGS World in 2012 | GenomeWeb

This story was originally published Dec. 31, 2012.

The next-gen sequencing sector kicked off 2012 with a hostile attempt from Roche to take over Illumina and ended with both BGI and Illumina pursuing Complete Genomics, bookending a year that saw a number of business deals — both successful and failed — from companies looking to bolster their positions in the increasingly competitive next-gen world.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.